Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Prostate Cancer
Phase III Trial: Provenge extends survival in advanced prostate cancer patients
August 26th, 2005
Dendreon Corp. (DNDN) announced that the analysis of the final 3-year survival data of its second phase III study (D9902A) of Provenge, the company's investigational active immunotherapy for the treatment of prostate cancer, showed a survival benefit in men with advanced prostate cancer who were treated with Provenge. Prostate cancer is the most commonly diagnosed nonskin cancer in the United States and the third-most-common cancer worldwide. In the D9902A study, the 3-year final survival analysis in the intent-to-treat population of the double-blind, placebo-controlled study of Provenge in 98 men with asymptomatic, metastatic, androgen-independent...
Source: Drug Week (2005-08-26)
|
